论文部分内容阅读
目的评价亚胺培南等10种抗菌药物对类鼻疽伯克霍尔德菌的体外抗菌活性。方法所有菌株用VITEK2-compact分析仪鉴定到种,药物敏感试验用E-Test法进行,结果按照CLSI(2010版)推荐标准进行分析。结果收集2009~2013年临床非重复分离类鼻疽伯克霍尔德菌101株,2012年该菌的检出与前三年比较差异具有统计学意义(P<0.05)。亚胺培南等10种抗菌药物对类鼻疽伯克霍尔德菌体外抗菌活性显示:亚胺培南的MIC50/MIC90最低,分别为0.25/0.38(mg/L);其次为哌拉西林/三唑巴坦,MIC50/MIC90分别为0.38/0.5(mg/L);美罗培南、头孢他啶、复方新诺明、左氧氟沙星、四环素、多西环素、阿莫西林/棒酸、头孢哌酮/舒巴坦的MIC50/MIC90分别为0.5/0.75、1.0/2.0、0.5/4.0、1.0/2.0、0.5/8.0、0.5/8.0、1.5/8.0、4.0/6.0(mg/L)。结论海南地区类鼻疽伯克霍尔德菌感染呈逐年增加趋势,亚胺培南是治疗类鼻疽伯克霍尔德菌感染的最佳药物。
Objective To evaluate the in vitro antibacterial activity of ten antibacterials, such as imipenem, against Burkholderia pseudomallei. Methods All strains were identified by VITEK2-compact analyzer. The drug susceptibility test was performed by E-Test. The results were analyzed according to the CLSI (2010 version) recommendation. Results 101 strains of Burkholderia pseudomallei isolated from 2009 to 2013 were collected. There was significant difference between the detection of this bacterium and the first three years in 2012 (P <0.05). In vitro antibacterial activity of ten antibacterials such as imipenem against Burkholderia pseudomallei showed that the MIC50 / MIC90 of imipenem were the lowest, 0.25 / 0.38 (mg / L) respectively, followed by piperacillin / Tazobactam, MIC50 / MIC90 were 0.38 / 0.5 (mg / L); Meropenem, ceftazidime, cotrimoxazole, levofloxacin, tetracycline, doxycycline, amoxicillin / clavulanic acid, cefoperazone / The potency of the antagonist was significantly higher than that of the control. The MIC50 / MIC90 of Bartan was 0.5 / 0.75,1.0 / 2.0,0.5 / 4.0,1.0 / 2.0,0.5 / 8.0,0.5 / 8.0,1.5 / 8.0,4.0 / 6.0 (mg / L) Conclusions The incidence of Burkholderia pseudomallei in Hainan is increasing year by year. Imipenem is the best drug for the treatment of Burkholderia pseudomallei.